Blackhawk’s MindBio Therapeutics Announces Completion of World First Phase 1 Microdosing Clinical Trial

• Successful completion of Phase 1 Clinical Trials 

• MindBio remains the only organization in the world to have successfully obtained government approvals for a doctor to prescribe LSD (lysergic acid diethylamide) to patients to take the drug unsupervised in the community in the same way they would take any other medicine 

• Phase 1 clinical trial report and safety data is being analyzed and will be announced shortly 

• Phase 2 clinical trials currently in development 

• MindBio spin-out plans progressing as scheduled 

Vancouver, British Columbia – TheNewswire - May 3rd, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC: BLRZF); (Frankfurt:0JJ) (the "Company" or "Blackhawk") is pleased to report that MindBio Therapeutics ("MindBio") has completed its 12 month Phase 1 clinical trial microdosing LSD in 80 healthy participants.

MindBio is developing a microdosing regimen using LSD to treat mental health disorders such as depression.  To get these novel treatments to market, MindBio needs to prove safety and efficacy of the treatment using a rigorous clinical trial process.

The Phase 1 Clinical Trial is the largest safety study of its kind that has ever been completed under a randomized, double blind placebo controlled discipline, the results of which will support development of MindBio's intellectual property and progression towards commercialization of treatments for mental health conditions.

MindBio is looking forward to analyzing the data from the Phase 1 clinical trial ...

Full story available on Benzinga.com

Read More